A major issue with treatment response and ultimate prognosis in NSCLC has until recently been dependent on morphologic information provided by standard chest radiography and CT. Unfortunately, these imaging techniques cannot reliably distinguish necrotic tumor

or fibrotic scar from residual tumor tissue [24]. Response evaluation with radiography and CT does not correlate well with histopathological response, and tumor response is determined more by residual tumor aggressiveness than by its size/volume [25]. Many studies have shown the sensitivity and specificity of PET for assessing histopathological response of NSCLC ranging between 81% and 97%, and 64% and 100%, respectively [26]. Thus, FDG-PET/CT is regarded as a predictor of treatment response and a prognosticator [27]. FDG-PET/CT has also been used in pre-operative assessment of prognosis of NSCLC [28]. The standard uptake values (SUV) of NSCLC measured Belnacasan purchase pre-operatively correlates with tumor doubling times and on a multivariate analysis, was an independent predictor of disease relapse and death [29] and [30]. Huang et al. have shown that SUV and metabolic tumor volume (MTV) changes from two serial FDG-PET/CT scans, before and after initial chemoradiotherapy,

Pifithrin-�� cell line allow prediction of the treatment response in advanced NSCLC [31]. PET/CT or PET are indicated for evaluation of mediastinum or for metastasis at initial evaluation for patient with resectable with curative intent

in tumor stage IA–IIIB [16] and [35] “
“The 7th edition of TNM Staging in lung cancer is the first classification to be based upon global data. The revisions are entirely based on the recommendations of the International Association for the Study Lung Cancer (IASLC) Staging Project, derived from the IASLC International Database for Lung Cancer, and were accepted ADAMTS5 without change by the International Union for Cancer Control (UICC) and the American Joint Commission on Cancer (AJCC). Data were collected from 46 databases in more than 20 countries around the world. 81,495 were available for final analysis, 68,463 cases of Non Small Cell Lung Cancer (NSCLC) and 13,032 cases of small-cell lung cancer (SCLC). Data on cases treated by all modalities of care have been intensively validated internally and externally [1]. a. Size cut points 3 cm is the cut point that separated T1 and T2 tumors was changed with introduction of new cut point at 2, 5, and 7 cm. T1 tumors are now subdivided into T1a and T1b around the 2 cm cut point. T2 tumors have been subdivided into T2a and T2b around the 5 cm cut point, and tumors >7 cm are now classified as T3 [2]. a. Down-staged T2a (>3 to ≤5 cm) N1 M0 from stage IIB to IIA. Some of these changes to stage groupings will have consequences for established treatment algorithms.